Rofecoxib [vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 551-560

  Chan, Chi Chung ^a   Boyce, S ^b   Brideau, C ^a   Charleson, S ^a   Cromlish, W ^a   Ethier, D ^a   Evans, J ^a   Ford Hutchinson, A W ^a   Forrest, M J ^b   Gauthier, J Y ^a   Gordon, R ^a   Gresser, M ^a   Guay, J ^a   Kargman, S ^a   Kennedy, B ^a   Leblanc, Y ^a   Leger, S ^a   Mancini, J ^a   O'Neill, G P ^a   Ouellet, M ^a   Patrick, D ^b   Percival, M D ^a   Perrier, H ^a   Prasit, P ^a   Rodger, I ^a   Tagari, P ^a   Therien, M ^a   Vickers, P ^a   Visco, D ^b   Wang, Z ^a   Webb, J ^b   Wong, E ^a   Xu, L J ^a   Young, R N ^a   Zamboni, R ^a   Riendeau, D ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; INDOMETACIN; METHYLCELLULOSE; NAPROXEN; PROSTAGLANDIN E2; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERALGESIA; NONHUMAN; OSTEOARTHRITIS; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONIC ACID; ARTHRITIS, EXPERIMENTAL; BLOOD PLATELETS; CELL LINE; COS CELLS; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DOGS; EDEMA; FEMALE; HUMANS; HYPERALGESIA; ISOENZYMES; LACTONES; LEUKOTRIENE B4; MALE; MEMBRANE PROTEINS; MICROSOMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED LEW; SAIMIRI; SULFONES;

EID: 0032788729     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Allison MC, Howatson AG, Torrance CJ, Lee FD and Russell RI (1992) Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327:749-754.
2. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC and Gregory SA (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97:2672-2679.
3. Brideau C, Kargman S, Liu S, Dallob AL, Ehich EW, Rodger IW and Chan C-C (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74.
4. Bjarnason I, Sigthorsson G, Crane R, Simon T, Hoover M, Bolognese J and Quan H (1998) COX-2 specific inhibition with MK-0966 25 or 50 mg q.d. does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg t.i.d. Am J Gastroenterol 93:1673.
5. Brooks P, Emery P, Evans J, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-Banos J, Kvien T, van Rijawijk MH, Warner T and Zeidler H (1999) Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Br J Rheumatol, in press.
6. Chan C-C, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li C-S, Mancini J, Penneton M, Prasit P, Rasori R, Riendeau D, Roy P, Tagari P, Vickers P, Wong E and Rodger IW (1995) Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274:1531-1537.
7. Chan C-C, Panneton M, Taylor AM, Therien M and Rodger IW (1997) A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. Eur J Pharmacol 327:221-225.
8. Clark RL, Cuttino JT Jr, Anderle SK, Cromartie WJ and Schwab JH (1979) Radiologic analysis of arthritis in rate after systemic injection of streptococcal cell walls. Arthritis Rheum 22:25-35.
9. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, Pick S and Trzaskos JM (1994) Mechanism of selective inhibition of the inducible isoform or prostaglandin G/H synthase. Proc Nad Acad Sci USA 91:11202-11206.
10. Cromlish WA and Kennedy BP (1996) Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochem Pharmacol 52:1777-1785.
11. Cryer B, Gottesdiener K, Gertz B, Hsieh P, Dallob A and Feldman M (1996) Effects of a novel cyclooxygenase (COX) -2 inhibitor on gastric mucosal prostaglandin synthesis in healthy humans. Am J Gastroenterol 91:1907.
12. Depre M, Ehrich E, DeLepeleire I, Dallob A, van Hecken A, Hilliard D, Tanaka W, Wong P, Buntinx A, Gertz B and DeSchepper P (1998) Demonstration of specific COX-2 inhibition by MK-966 (VIOXX) in humans with supratherapeutic doses. Rheum Eur 27(Suppl 2):118.
13. Ehrich EW, Dallob A, DeLepeleire I, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, DeSchepper P, Mehlishch D and Gertz BJ (1999) Characterization of rofecoxib as a cyclooxygenase 2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65:336-347.
14. Ehrich E, Schnitzer T, Weaver A, McKay Brabham A, Schiff M, Ko A, Brett C, Bolognese J and Seidenberg B (1998a) Treatment with MK-0966 (VIOXX), a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee and hip, that was sustained over six months. Rheumatol Eur 27(Suppl 2):198.
15. Ehrich E, Bolognese J, Watson DJ, Kong S, Stem S, Mease P, Zeng Q and Seidenberg B (1998b) The effect of MK-0966 (VIOXX), a COX-2 specific inhibitor, on health-related quality-of-life in osteoarthritis patients. Rheumatol Eur 27(Suppl 2):197.
16. Ehrich E, Dallob A, van Hecken A, Depre M, DeLepeleire I, Brideau C, Hillard D, Tanaka W, Mukhopadhyay S, Seibold J, DeSchepper P and Gertz B (1996) Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis Rheum 39(Suppl 9):A328.
17. Fletcher DS, Widmer WR, Luell S, Christen AJ, Orevillo C, Shah C and Visco DM (1998) Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J Pharmacol Exp Ther 284:714-721.
18. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H and Otomo S (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 24:105-110.
19. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA and Birch PJ (1995) Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and COX 2 inhibitors. Inflamm Res 44:253-257.
20. Hunt R, Bowen B, James C, Sridhar S, Simon T, Mortensen E, Cagliola A, Quan H and Bolognese J (1998) COX-2 specific inhibition with MK-0966 25 or 50mg q.d. over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg t.i.d. Am J Gastroenterol 93:1671.
21. Kargman S, Wong E, Greig GM, Falgueyret J-P, CromLish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA and O'Neill GP (1996) Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol 52:1113-1125.
22. Lanza F, Simon T, Quan H, Bolognese J, Rack MF, Hoover M and Wilson F (1997) Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg, q.d.) is associated with less gastroduodenal damage than aspirin 650mg q.i.d. or ibuprofen 800 mg t.i.d. Gastroenterology 112(Suppl 4):A194.
23. Meade EA, Smith WL and DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide aynthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614.
24. Murray MD and Brater DC (1993) Renal toxicity of the nonsteroidal antiinflammatory drugs. Ann Rev Pharmacol Toxicol 33:435-465.
25. O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret J-P, Abramovitz M, Kennedy BP, Ouellet M, Cromlish W, Culp S, Evans JF, Ford-Hutchinson AW and Vickers PJ (1994) Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal antiinflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 45:245-254.
26. Ouellet M and Percival MD (1995) Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 306:247-251.
27. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J and Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide syntheses. J Pharmacol Exp Ther 271:1705-1712.
28. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347-1365.
29. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 269:15619-15624.
30. Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E and Guay J (1997a) Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol 75:1088-1095.
31. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret J-P, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Leger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Therien M, Wang Z, Webb JK, Wong E, Xu L, Young RN, Zamboni R, Prasit P and Chan C-C (1997b) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121:105-117.
32. Schafer AI (1995) Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 35:209-219.
33. Schwartz JI, Chan C-C, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, Davidson MH, Bachmann KA, Gertz BJ (1999) Selective inhibition of cyclooxygenase type-2 reverses endotoxin-induced fever in monkeys and naturally ocurring fever in humans. Clin Pharmacol Ther, in press.
34. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L and Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017.
35. Smith WL and DeWitt DL (1996) Proataglandin endoperoxide H synthases-1 and -2. Adv Immunol 62:167-215.
36. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drags. Nat New Biol 231:232-235.
37. Vane JR and Botting RM (1995) New insights into the mode of action of antiinflammatory drugs. Inflamm Res 44:1-10.
38. Wong E, DeLuca C, Boily C, Charleson S, Cromlish W, Denis D, Kargman S, Kennedy BP, Ouellet M, Skorey K, O'Neill GP, Vickers PJ and Riendeau D (1997) Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm Res 46:51-59.
39. Young JM, Panah S, Satchawatcharaphong C and Cheung PS (1996) Human whole blood assays for inhibition of prostaglandin G/H synthase-1 and -2 using A23187 and lipopolysaccharide stimulation of thomboxane B2 production. Inflamm Res 45:246-253.